甲苯达唑治疗及维持治疗卵巢癌的潜力与机制
本研究在细胞培养和体内模型(包括顺铂耐药的高级别浆液性3C期卵巢癌患者来源异种移植模型PDX-0003(p53缺失)和PDX-0030(p53阳性))中评估甲苯达唑的抗癌疗效。甲苯达唑在纳摩尔浓度下抑制卵巢癌细胞培养生长,在高达50 mg/kg剂量下抑制PDX生长,并在50 mg/kg下减少原位肿瘤建立。其机制与不依赖p53的p21诱导和微管解聚相关。PRIMA-1MET也抑制肿瘤建立,并与甲苯达唑在细胞培养中协同抑制生长并诱导内源性凋亡。
要点
- 甲苯达唑在纳摩尔浓度抑制卵巢癌细胞生长,50 mg/kg抑制PDX生长和原位肿瘤建立。
- 甲苯达唑机制涉及不依赖p53的p21诱导和微管解聚。
- PRIMA-1MET与甲苯达唑协同抑制生长并诱导凋亡,机制不依赖p53和微管解聚。
核心结论
- 甲苯达唑具有重定位治疗卵巢癌的潜力,支持其临床开发用于卵巢癌治疗和维持治疗。
研究设计与样本
- 研究在顺铂耐药的高级别浆液性3C期卵巢癌PDX模型(PDX-0003 p53缺失和PDX-0030 p53阳性)及多种卵巢癌细胞系中评估甲苯达唑。
- 采用等辐射图、克隆形成实验和蛋白质印迹评估药物协同作用和机制,并在MES-OV原位模型中研究肿瘤建立预防。
主要发现
- 甲苯达唑在纳摩尔浓度下抑制卵巢癌细胞培养生长,在高达50 mg/kg剂量下抑制PDX生长,并在50 mg/kg下减少原位肿瘤建立。
- 甲苯达唑机制与不依赖p53的p21诱导和微管解聚相关。
- PRIMA-1MET抑制肿瘤建立,并与甲苯达唑在细胞培养中协同抑制生长和诱导内源性凋亡,机制不依赖p53和微管解聚。
临床怎么用
- 基于临床前证据,甲苯达唑可考虑用于卵巢癌治疗和维持治疗的临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mebendazole and other anti-parasitic drugs are being used off-prescription based on social media and unofficial accounts of their anti-cancer activity. The purpose of this study was to conduct a controlled evaluation of mebendazole's therapeutic efficacy in cell culture and in vivo models of ovarian cancer. The majority of ovarian cancers harbor p53 null or missense mutations, therefore the effects of p53 mutations and a mutant p53 reactivator, PRIMA-1MET (APR246) on mebendazole activity were evaluated. METHODS: Mebendazole was evaluated in cisplatin-resistant high grade serous stage 3C ovarian cancer patient derived xenograft (PDX) models: PDX-0003 (p53 null) and PDX-0030 (p53 positive), and on ovarian cancer cell lines: MES-OV (p53 R282W), ES2 (p53 S241F), A2780 (p53 wild type), SKOV3 parental (p53 null) and isogenic sublines, SKOV3 R273H p53 and SKOV3 R248W p53. Drug synergy and mechanisms were evaluated in cell cultures using isobolograms, clonogenic assays and western blots. Prevention of tumor establishment was studied in a MES-OV orthotopic model. RESULTS: Mebendazole inhibited growth of ovarian cancer cell cultures at nanomolar concentrations and PDXs at doses up to 50 mg/kg, and reduced orthotopic tumor establishment at 50 mg/kg. The mechanism of mebendazole was associated with p53-independent induction of p21 and tubule depolymerization. PRIMA-1MET also inhibited tumor establishment and worked synergistically with mebendazole in cell culture to inhibit growth and induce intrinsic apoptosis through a p53- and tubule destabilization-independent mechanism. CONCLUSION: This work demonstrates the therapeutic potential of repurposing mebendazole and supports clinical development of mebendazole for ovarian cancer therapy and maintenance.
引用
- Elayapillai S, Ramraj S, Benbrook DM, et al. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2020. PMID: 33131904. doi:10.1016/j.ygyno.2020.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。